Reports Q4 revenue $2.5M, consensus $1.43M. As of December 31, 2018, Ra Pharma reported total cash and cash equivalents of $209.8M. The company expects that its cash and cash equivalents will be sufficient to fund operating expenses and capital expenditures through at least the first quarter of 2021.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.